1. Localized targeted antiangiogenic drug delivery for glioblastoma

   • Gregory D. Arnone
   • Abhiraj D. Bhimani
   • Ankit I. Mehta

   Topic Review 11 January 2018 Pages: 223 - 231

2. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol

   • C. J. O’Regan
   • H. Kearney
   • P. G. Buckley

   Laboratory Investigation 20 December 2017 Pages: 233 - 240

   

3. Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma

   • Noble Kumar Talari
   • Manas K. Panigrahi
   • Prakash Babu Phanithi

   Laboratory Investigation 04 January 2018 Pages: 241 - 248

   

4. Analysis of immunobiologic markers in primary and recurrent glioblastoma

   • Maryam Rahman
   • Jesse Kresak
   • Duane Mitchell

   Laboratory Investigation 04 January 2018 Pages: 249 - 257

   

5. A combined diffusion tensor imaging and Ki-67 labeling index study for evaluating the extent of tumor infiltration using the F98 rat glioma model

   • Kai Wang
   • Tingting Ha
   • Jianping Dai

   Laboratory Investigation 02 January 2018 Pages: 259 - 268

   

6. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response

   • Ashley S. Plant
   • Shohei Koyama
   • Jerome Ritz

   Laboratory Investigation 10 January 2018 Pages: 269 - 278

   

7. Sex-dependent association of preoperative hematologic markers with glioma grade and progression

   • Wenshen Xu
   • Dengliang Wang
   • Liming Huang

   Clinical Study 19 December 2017 Pages: 279 - 287

   

8. Recursive partitioning analysis is predictive of overall survival for patients undergoing spine stereotactic radiosurgery

   • Ehsan H. Balagamwala
   • Jacob A. Miller
   • Samuel T. Chao

   Clinical Study 03 January 2018 Pages: 289 - 293

   

9. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis

   • Jaehag Jung
   • Seung Hoon Lee
   • Heon Yoo

   Clinical Study Open access 19 December 2017 Pages: 295 - 302

   

10. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma

    • Deborah R. Smith
    • Cheng-Chia Wu
    • Tony J. C. Wang

    Clinical Study 20 December 2017 Pages: 303 - 311

    

11. Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG)

    • Lei Qin
    • Angie Li
    • Geoffrey S. Young

    Clinical Study 30 January 2018 Pages: 313 - 319

    

12. The impact of a mind–body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis

    • Emily L. Zale
    • Catherine Pierre-Louis
    • Ana-Maria Vranceanu

    Clinical Study 23 December 2017 Pages: 321 - 329

    

13. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?

    • Pedro Góes
    • Bruno Fernandes Oliveira Santos
    • Manoel Antônio de Paiva Neto

    Clinical Study 21 December 2017 Pages: 331 - 336

    

14. PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity

    • Kavitha Nutakki
    • James W. Varni
    • Nancy L. Swigonski

    Clinical Study 22 December 2017 Pages: 337 - 347

15. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

    • Katherine B. Peters
    • Eric S. Lipp
    • Henry S. Friedman

    Clinical Study 21 December 2017 Pages: 349 - 356

    

16. Update on the effect of exogenous hormone use on glioma risk in women: a meta-analysis of case-control and cohort studies

    • Yu-Long Lan
    • Xun Wang
    • Bo Zhang

    Clinical Study 26 December 2017 Pages: 357 - 365

    

17. Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study

    • Jaume Capellades
    • Josep Puig
    • Carmen Balaña

    Clinical Study 28 December 2017 Pages: 367 - 377

    

18. To drive or not to drive, that is still the question: current challenges in driving recommendations for patients with brain tumours

    • Ann Mansur
    • Alexa Desimone
    • Sunit Das

    Clinical Study 02 January 2018 Pages: 379 - 385

    

19. Treatment and outcomes of 28 patients with spinal metastasis from gynecological cancer

    • Xin Gao
    • Chenglong Zhao
    • Jianru Xiao

    Clinical Study 18 January 2018 Pages: 387 - 394

    

20. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma

    • Yuan-Bo Pan
    • Chi-Hao Zhang
    • Dong-Fu Feng

    Clinical Study 02 January 2018 Pages: 395 - 407

    

21. Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study

    • Alysson Wann
    • Patrick A. Tully
    • Mustafa Khasraw

    Clinical Study 02 January 2018 Pages: 409 - 415

    

22. Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system

    • Ichiyo Shibahara
    • Mitsuto Hanihara
    • Toshihiro Kumabe

    Clinical Study 21 February 2018 Pages: 417 - 427

    

23. Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy

    • David Thibouw
    • Gilles Truc
    • Céline Mirjolet

    Clinical Study 27 January 2018 Pages: 429 - 438

    

24. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients

    • J. N. Jakobsen
    • T. Urup
    • H. S. Poulsen

    Clinical Study 12 January 2018 Pages: 439 - 446